Connecting the dots...Provectus Biopharmaceuticals: Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity

March 26, 2012

Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity

Following its Friday PR -- Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response: (i) Leads to Regression of Untreated Lung and Cutaneous Melanoma Metastases and (ii) Results Detailed in Poster Presentation at the Society of Surgical Oncology Annual Meeting; Details of Poster Expected to Be Released Next Week -- Provectus released the second immunology-/SSO-related PR today.

The poster is below:

I below up some of the portions of the poster.

No comments:

Post a Comment

Disclaimer

This blog is neither intended to be nor is investment advice. The author of this blog (the "Author") is not a registered investment advisor. Under no circumstances should any content from this blog be used or interpreted as a recommendation of a trade or investment in Provectus Biopharmaceuticals, Inc. Trading and investing can be hazardous to your wealth, health or both. Any investment decision must, in all cases and without exception, be made by the reader or by his or her registered investment advisor. This blog is only and strictly for educational and informational purposes. The Author may have a position in Provectus Biopharmaceuticals, Inc. at any given time that is not disclosed at the time of publication. All opinions expressed by the Author are subject to change without notice. You, the reader, should always obtain current information and perform the appropriate due diligence before making any investment or trading decision. All efforts are made to ensure the information contained in the blog and/or a blog post is factual and accurate; however, the Author does not guarantee its accuracy under any circumstances.

♢ Note: Provectus' board of directors appointed the Author as a special adviser to the board in February 2017. See the blog's Disclosures page.

♢♢ Note: The Author and others entered into a securities transaction with Provectus. See the blog's Disclosures page.